Mandate

Vinge advises Sigrid Therapeuctis AB on share issues

November 27, 2017

Vinge has advised Sigrid Therapeuctis AB in connection with a combined directed issue and rights offering.

Sigrid Therapeutics is pioneering a user-friendly product made of precisely engineered particles with extraordinary absorptive capacity. The product works mechanically in the gut to improve glycemic control in a safe and effective way.

Vinge’s team primarily consisted of Kristoffer Franzkeit and Astrid Karlsson.

Related

Vinge advises Sveafastigheter on the establishment of its EMTN programme and issuance of EUR 300 million bonds

Vinge has advised Sveafastigheter AB (publ) as Swedish legal counsel on the establishment of a euro medium-term note programme (the “EMTN programme”) with a framework of EUR 2 billion and the issuance of senior unsecured bonds totalling EUR 300 million under the EMTN programme.
January 23, 2026

Vinge advises EQT AB on its combination with Coller Capital

Vinge advises EQT AB on its acquisition Coller Capital, a global secondaries firm with nearly USD 50 billion in total assets under management across institutional, private wealth and insurance-related capital.
January 22, 2026

Vinge advises Nordic Re-Finance AB on a Swedish railway financing

Vinge has acted as Swedish legal counsel to Nordic Re-Finance AB, a leading lessor of locomotives for rail freight traffic in Scandinavia, in connection with the execution of a EUR 250m debt package fully underwritten by Natixis CIB.
January 21, 2026